Trial Information

Summary: Child Studies: Attention Deficit Hyperactivity Disorder

A Phase IV, Multi-Center, Open-Label Study of Daytrana ™, Methylphenidate Transdermal System (MTS) to Characterize the Dermal Reactions in Pediatric Patients Aged 6 - 12 with Attention-Deficit/Hyperactivity Disorder (ADHD).

We are currently conducting a 14-week research study in children with Attention Deficit/Hyperactivity Disorder (ADHD). People who suffer from ADHD can experience difficulty paying close attention to details, make careless mistakes, fidget with their hands or feet, lose things necessary for tasks, have difficulty organizing tasks and/or talk excessively. If your child is suffering from ADHD, you may be eligible to enroll them in this research study.

To be eligible to participate, your child must:

• Be between the ages of 6 and 12
• Be in good health
• Meet criteria for ADHD
• Have no skin allergies that would prohibit wearing a patch containing medication

All study related clinic visits, testing, and study medications are provided at no cost.

To learn more about potential benefits and risks of this study,

If you would like to learn more about participating in this study, please send an e-mail message using the form below.